-- 加拿大皇家银行资本市场（RBC Capital Markets）周二发布的研究报告指出，Cytokinetics公司（股票代码：CYTK）旗下药物Myqorzo的快速增长以及其在美国治疗梗阻性肥厚型心肌病（HCM）的巨大市场潜力尚未被投资者充分消化。 该券商表示，随着Cytokinetics从临床阶段过渡到商业化阶段，预计Myqorzo的上市执行和潜在的并购选择将带来利好。如果该公司继续保持每月新增400至500例患者，则有望在全年实现显著的商业增长。 报告指出，由于大部分运营障碍已经克服，Myqorzo的库存贡献不大，这印证了市场对其存在内生性需求的观点。 该券商认为，用于治疗症状性非梗阻性肥厚型心肌病的ACACIA-HCM适应症是一项“显著的胜利”，有望推动该适应症的注册。 RBC表示，已将该药物的成功概率预测上调至90%，并将2035年美国销售额预期上调至13亿美元。 该公司取消了对该股票的投机性风险评级，并将目标股价从每股101美元上调至119美元。
Price: $73.59, Change: $-3.50, Percent Change: -4.54%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%